Because our analysis showed a tendency for upregulation of EHHADH expression in patients with cisplatin resistance in spite of the small sample size and bias, the results suggest that EHHADH could be a new molecular target and marker for progressive BC. The gene discussed is EHHADH; the disease is breast cancer.